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Abstract
Persisters are a subpopulation of normal bacterial cells that show tolerance to conventional
antibiotics. Persister cells are responsible for recalcitrant chronic infections and new antibi-
otics effective against persisters would be a major development in the treatment of these in-
fections. Using the reporter dye SYTOXGreen that only stains cells with permeabilized
membranes, we developed a fluorescence-based screening assay in a 384-well format for
identifying compounds that can kill methicillin-resistant Staphylococcus aureus (MRSA)
persisters. The assay proved robust and suitable for high throughput screening (Z`-factor:
>0.7). In screening a library of hits from a previous screen, which identified compounds that
had the ability to block killing of the nematode Caenorhabditis by MRSA, we discovered that
the low molecular weight compound NH125, a bacterial histidine kinase inhibitor, kills
MRSA persisters by causing cell membrane permeabilization, and that 5 μg/mL of the com-
pound can kill all cells to the limit of detection in a 108 CFU/mL culture of MRSA persisters
within 3h. Furthermore, NH125 disrupts 50% of established MRSA biofilms at 20 μg/mL and
completely eradicates biofilms at 160 μg/mL. Our results suggest that the SYTOX Green
screening assay is suitable for large-scale projects to identify small molecules effective
against MRSA persisters and should be easily adaptable to a broad range of pathogens
that form persisters. Since NH125 has strong bactericidal properties against MRSA persist-
ers and high selectivity to bacteria, we believe NH125 is a good anti-MRSA candidate drug
that should be further evaluated.
Introduction
A significant challenge in the treatment of bacterial infections has been the appearance of anti-
biotic-resistant strains as a consequence of mutation or the acquisition of antibiotic resistance
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genes through horizontal gene transfer, as well as the transient reversible selection of antibiot-
ic-tolerant persister cells during antibiotic therapy in individual patients. Most current antibi-
otics target essential biosynthetic processes such as DNA replication, protein synthesis, or cell
wall synthesis that occur during bacterial growth [1,2]. Antibiotic resistance can be caused by
enzymes that degrade or modify the antibiotic, efflux pumps that export the antibiotic, or mu-
tations that modify antibiotic targets [1]. A well-known example of antibiotic resistance is
methicillin-resistant Staphylococcus aureus (MRSA), which was first identified in the 1960s as a
hospital-acquired infection [3], but in recent years has been increasingly prevalent in the gener-
al population (community-associated MRSA) [4]. S. aureus causes approximately 10,800
deaths per year in the United States and approximately 50% of these are due to MRSA [5].
Moreover, although vancomycin is currently used to treat MRSA as an antibiotic of last resort,
vancomycin-resistant S. aureus (VRSA) strains have started to emerge, motivating the urgent
development of new antibiotics effective against antibiotic-resistant S. aureus [6].
In contrast to antibiotic-resistant bacteria such as MRSA, antibiotic-tolerant bacteria,
known as persisters, are phenotypic variants that exist as a subpopulation of normal cells. Per-
sisters are non-growing dormant bacteria where the targets for most conventional antibiotics
are inactive [7,8]. Persisters were first identified by Bigger in 1944 [9], but the molecular mech-
anisms underlying persister formation are still only partially understood. Recent studies have
shown that toxin-antitoxin (TA) modules play an important role in persister formation [10].
Under specific stresses, antitoxins are degraded and the resulting active toxins inhibit cellular
processes, which eventually leads to persister formation [8]. Recent studies have shown that
persisters are involved in chronic infections and are responsible for the recalcitrance of chronic
infections to antibiotic chemotherapy [11,12]. Importantly, persisters are also responsible for
the antibiotic tolerance of biofilms [13], surface-associated microbial communities encapsulat-
ed by a self-produced extracellular polymeric matrix, that are involved in up to 65% of bacterial
infections in developed countries [14].
The bacterial cell envelope consisting of the bacterial membrane and cell wall is a promising
target for novel antibiotics that would potentially be effective against both normal and persister
cells. The bacterial cell envelope is essential for cell survival and contains about 30% of bacterial
proteins, many of which are essential for survival [15–17]. Indeed, many types of antibiotics
that target the cell envelope, including proteins, peptides, and small molecules, have been
shown to be efficacious against S. aureus [17–22]. For instance, lysostaphin and endolysins kill
S. aureus by hydrolyzing peptidoglycan, which results in membrane permeabilization [18–20].
Nisin A, daptomycin and telavancin kill S. aureus by inducing membrane permeabilization
and depolarization [17,22]. Although their specific modes of action are different, the common
feature of these agents is that each directly or indirectly induces rapid membrane permeabiliza-
tion, which correlates with bactericidal activity [20,22,23].
We hypothesized that antibiotic agents inducing rapid permeabilization of cell membranes
should be effective drugs against MRSA persisters and could be identified using SYTOX
Green, a DNA-binding dye that can readily penetrate and stain cells with compromised mem-
branes, but not live cells with intact membranes [24]. Herein, we describe a fluorescence-based
screening assay to identify antimicrobial agents that eradicate MRSA persisters by inducing
membrane permeabilization. Using this method, we screened a library of antimicrobial com-
pounds previously identified using a high throughput C. elegans—MRSA assay [25] and identi-
fied NH125 (1-Hexadecyl-2-methyl-3-(phenylmethyl)-1H-imidazolium iodide) as a hit
compound that kills MRSA persisters and eradicates MRSA biofilms. To our knowledge, this is
the first high-throughput screening assay for systematically identifying drugs targeting MRSA
persisters.
Screening of Small Molecules against Persisters
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Materials and Methods
Bacterial strains, growth conditions, and persister isolation
Community-acquired methicillin-resistance S. aureus (CA-MRSA) strain MW2 BAA-170 was
obtained from ATCC (Manassas, VA, USA). To isolate persister cells, overnight cultures of
MW2 grown in tryptic soy broth (TSB) (BD) at 37°C were treated with 10X MIC (20 μg/mL)
gentamicin for 4 h [26].
Antimicrobial agents and chemicals
All antibiotics except for NH125 were purchased from Sigma-Aldrich. NH125 was purchased
from Tocris Bioscience. 10 mg/mL stock solutions of all antibiotics except for nisin A were
made in DMSO or ddH2O. As described in a previous study [27], nisin A (hereafter nisin)
stock solutions were prepared in 0.02N HCl at a concentration of 250 μg/ml. Lysostaphin-
treated samples were supplemented with 0.1% bovine serum albumin (BSA) to prevent non-
specific adherence to plastic surfaces [28].
Persister membrane permeability assay
Black, clear-bottom 96-well plates (Corning no. 3904) were filled with 50 μL of PBS/well con-
taining the indicated concentration of antibiotics. To isolate MRSA persisters, 25 mL of an
S. aureusMW2 culture was grown to stationary phase and then treated with gentamicin at
20 μg/mL for 4 h, as described above. Then bacteria were washed 3 times with the same volume
of phosphate buffered saline (PBS). The washed cells were diluted to OD600 = 0.4 (~2 x 10
8
CFU/mL) with PBS. SYTOX Green (Molecular Probes) was added to 10 mL of the diluted per-
sister suspension to a final concentration of 5 μM and incubated for 30 min at room temperature
in the dark. 50 μL of the persister/SYTOX Green mixture was added to each well of 96-well plates
containing antibiotics and fluorescence was measured at room temperature for up to 4 h using a
spectrophotometer (SpectraMax M3, Molecular Devices) with excitation and emission wave-
lengths of 485 and 525 nm, respectively. All experiments were conducted in triplicate.
Time course assay
Persister cells were prepared by treating 25 mL of an S. aureusMW2 culture in stationary
phase with gentamicin at 20 μg/mL for 4 h, as described above. The isolated persisters were
washed 3 times with PBS and diluted to OD600 0.4 (~2 x 10
8 CFU/mL) with the same buffer.
1 mL of the persister suspension containing 10X MICs of indicated antibiotics was added to
the wells of a 2 mL deep well assay block (Corning Costar 3960) and incubated at 37°C, with
shaking at 225 rpm. At specific times, 50 μL samples were removed, serially diluted, and spot-
plated on tryptic soy agar (TSA, BD) plates to enumerate the number of persister cells. These
experiments were also conducted in triplicate.
Compound screening
We previously described a high throughput assay for identifying compounds that block the
ability of MRSA strain MW2 to kill C. elegans animals [25]. This assay was used to screen ap-
proximately 85,000 compounds obtained from the Institute of Chemistry and Chemical Biolo-
gy, Harvard Medical School. Among the hits obtained in this screen, which will be described in
detail in a separate publication, 101 compounds with antimicrobial properties against MRSA
were chosen for a secondary screen to identify compounds that kill persister cells on the basis
of their ability to induce permeabilization of MRSA membranes. A black, clear-bottom
384-well plate (Corning no. 3712) was filled with 20 μL of PBS containing 20 μg/mL of each
Screening of Small Molecules against Persisters
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compound from the library. 20 μL of the MRSA persister/SYTOX Green mixture prepared as
described above was added into each well of the 384-well plate containing compounds. 0.1% di-
methyl sulfoxide (DMSO) or 1.25 μg/mL lysostaphin were included in two columns as negative
and positive controls, respectively. Fluorescence was measured as described above. To identify
hits, a Z-score was calculated from the fluorescence intensity data; Z-score = (x-μ)/σ where x is
the fluorescence intensity of each sample, μ is the mean of the sample population, and σ is the
standard deviation of the sample population [29]. Samples with a Z-score>3 were
considered hits.
Z’-factor evaluation for assay quality
The robustness of the screening assay was evaluated based on the Z’-factor [30]. Z’-factor = 1-
((3σp+3σn)/|μp-μn|) where σp and σn are the standard deviations of the positive and negative
controls, respectively and μp and μn are the means of the positive and negative controls, respec-
tively [30]. 1>Z’-factor0.5 indicates a robust assay [30]. Fluorescence intensity data from a
384-well plate where half of the wells were filled with 0.1% DMSO (negative control) and the
remaining wells contained 1.25 μg/mL lysostaphin or 80 μg/mL nisin (positive controls) were
used to calculate the Z’-factor.
Minimal inhibitory concentration (MIC) assay
The MICs of antibiotics were determined by the standard micro-dilution method recom-
mended by the Clinical and Laboratory Standards Institute [31]. The assay was conducted
in triplicate.
Biofilm persister viability assay
An overnight culture of cells was diluted 1:200 with TSB supplemented with 0.2% glucose and
3% NaCl [32]. A 13 mm diameter Millipore mixed cellulose ester membrane was placed at the
bottom of each well of a 12-well plate (Falcon 353043). 1 mL of the diluted culture was added
to each well and incubated statically at 37°C for 24 h. To remove planktonic cells, the mem-
branes were washed 3-times with PBS and transferred to a new 12-well plate. 1 mL of PBS with
10X MICs of antibiotics was added to each well and the plate was incubated statically at 37°C
for 24 h. The membranes were washed 3 times with PBS, placed in 1 mL PBS, and sonicated in
an ultrasonic bath (Fisher Scientific FS 30) for 10 min. The sonicated samples were serially di-
luted with PBS in a 96-well plate. The diluted samples were spot-plated on TSA plates and in-
cubated at 37°C overnight. The experiment was conducted in triplicate.
Biofilm disassembly assay
An overnight culture of S. aureusMW2 was diluted 1:200 with TSB supplemented with 0.2%
glucose and 3% NaCl [32]. 100 μL of the diluted culture was added to each well of a U-bot-
tomed 96-well microtiter plate (Falcon 353077). After 48 h of incubation at 37°C, the microtiter
plate was washed 3 times with sterile water. 100 μL of PBS including the indicated concentra-
tions of antibiotics were added to each well and incubated at 37°C for 24 h. After washing 3
times with water, the biofilm in each well was stained with 0.1% crystal violet (Sigma) for
15 min at room temperature. The plate was washed 3 times with water and then dried. The
crystal violet stain was solubilized with 125 μL of 95% ethanol for 15 min. 100 μL of solubilized
crystal violet from each sample well was transferred to a new flat-bottomed 96-well microtiter
plate and the amount of biofilm was determined by measuring the OD590 nm with a spectro-
photometer. The experiment was conducted in triplicate.
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Results
Isolation of MRSA persisters
In previous studies, persisters have been isolated from antibiotic-susceptible cell populations
by treating stationary phase cultures with a large dose of an antibiotic for 4 h [26,33]. To gener-
ate MRSA persisters, S. aureusMW2 was grown to stationary phase and then treated with
20 μg/mL (10X MIC) gentamicin for 4 h [26]. The concentration of cells in stationary phase
was ~1010 CFU/mL and, after treating with 20 μg/mL gentamicin for 4 h, the cell viability was
not decreased (Fig 1). To determine whether these cells are tolerant to other antibiotics in addi-
tion to gentamicin, we treated the gentamicin-tolerant cells with an additional dose of 10X
MIC gentamicin, or with ciprofloxacin (DNA synthesis inhibitor) or 10X MIC vancomycin
(cell wall synthesis inhibitor) for an additional 4 h. No decrease in viability was observed after
treating the gentamicin-tolerant cells with any of these antibiotics (Fig 1). Moreover, these gen-
tamicin-tolerant cells do not show a further decrease in viability after treating with 100X MIC
gentamicin, ciprofloxacin or vancomycin for 4 h (S1 Fig). These results indicated that essential-
ly all of the S. aureusMW2 cells in a stationary phase culture are in a persistent state, which is
consistent with previous studies showing that stationary-phase S. aureus cells are persisters
[26,33,34].
SYTOX Green assay to identify compounds that kill persister cells
Several potent antibiotics such as lysostaphin, nisin, and HT61 confer antimicrobial activity by
damaging the cell wall or membrane, which both directly and indirectly causes membrane per-
meabilization [20,22,35]. Because both actively dividing cells and persisters depend on an intact
cell envelope for viability, as noted above, we reasoned that antimicrobial compounds that
cause membrane permeabilization would be good candidates for potential drugs effective
against MRSA persisters. In order to identify such compounds, we developed an assay using
Fig 1. Isolation of MRSA persisters. An MRSA overnight culture was treated with 10X MIC (20 μg/mL)
gentamicin for 4 h and the titer of viable cells was determined. After the 4 h treatment with gentamicin, the
culture was treated with additional antibiotics at the indicated concentrations (10X MIC) for an additional 4 h,
followed by once again determining the titer of viable cells. Results are shown as means ± s.d.; n = 3. Gm:
gentamicin, Cipro: ciprofloxacin, Van: vancomycin.
doi:10.1371/journal.pone.0127640.g001
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the reporter dye SYTOX Green that is only taken up by cells with permeabilized membranes
and shows>500-fold signal enhancement upon binding to DNA [24].
As a proof-of-concept, we measured membrane permeability and viability of MRSA persist-
er cells after treatment with lysostaphin or nisin. As expected, both lysostaphin and nisin did
not only induce membrane permeabilization, but also killed persisters, as measured by CFU
counts, at a rate that was directly proportional to their concentration (Fig 2 and S2 Fig). In con-
trast, traditional antibiotics such as gentamicin, vancomycin, and ciprofloxacin at 10X MIC
did not cause membrane permeabilization or cell death (S3 Fig). In addition, we found a strong
correlation between membrane permeability as measured by the SYTOX Green assay and via-
bility (Fig 2 and S2 Fig). A correlation between membrane permeability and cell death was also
observed with an exponential-phase S. aureus culture treated with lysostaphin [20] or nisin
[36], suggesting that their bactericidal activities correlate with membrane permeabilization and
are the same in both growing and persister cells. These results support the hypothesis that anti-
microbial agents that kill MRSA persisters by inducing membrane permeabilization can be
identified using SYTOX Green.
High-throughput MRSA persister cell screen
The assay for identifying anti-persister drugs using SYTOX Green was adapted for HTS in
384-well microtiter plate format. The volume for the assay was adjusted to 40 μL per well, and
fluorescence intensity was measured 1 h after compounds were added, based on the expecta-
tion that effective compounds would induce rapid membrane permeabilization (Fig 2B and
2C). To evaluate the robustness and reproducibility of the assay, we determined the Z’-factor, a
statistical parameter of assay quality as noted in the Materials and Methods [30]. The Z’-factor
was calculated from fluorescence intensity data from a 384-well plate in which half of the wells
were filled with 0.1% DMSO (negative control) and the remaining wells contained 10X MIC of
lysostaphin or 10X MIC of nisin (positive controls). The Z’-factors calculated using lysostaphin
and nisin were 0.767 and 0.712, respectively (Fig 3), which indicated that this assay is robust
and suitable for large-scale, high throughput screening.
Pilot screen and identification of a compound that kills MRSA persisters
We previously screened 85,000 compounds obtained from the Institute of Chemistry and Cell
Biology (ICCB), Harvard Medical School, using a C. elegans-MRSA assay [25] (manuscript in
preparation) in order to identify anti-MRSA agents that are able to prolong the lifespan of C.
Fig 2. Lysostaphin and nisin kill MRSA persisters by inducingmembrane permeabilization.MRSA persisters were treated with 0.1% DMSO (A), 10X
MIC lysostaphin (B), or 10X MIC nisin (C). Membrane permeabilization (open circles) was measured spectrophotometrically by monitoring the uptake of
SYTOXGreen (excitation wavelength of 485 nm and an emission wavelength of 525 nm). Colony forming unit counts of persisters (solid circles) were
measured by serial dilution and plating on TSA plates. The data points on the x-axis are below the level of detection (2x102 CFU/mL). Results are shown as
means ± s.d.; n = 3.
doi:10.1371/journal.pone.0127640.g002
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elegans infected with MRSA. One of the advantages of this C. elegans-based screening strategy
is the ability to simultaneously assess toxicity and efficacy [25,37–40]. 101 anti-MRSA agents
that prolonged the life of MRSA-infected nematodes, identified using the C. elegans-MRSA
assay, were screened at 10 μg/mL utilizing the SYTOX Green permeability assay. To identify
hits, Z-scores were calculated from the fluorescence intensity data.
Among the 101 compounds, NH125 (1-Hexadecyl-2-methyl-3-(phenylmethyl)-1H-imida-
zolium iodide) was identified as a hit with a Z-score of 10.61 (Fig 4A). NH125 is known to be
an antibiotic and has been shown to inhibit bacterial histidine kinases and eukaryotic elonga-
tion factor 2 kinase [41–43]. Consistent with previous work [41,42], the MIC of NH125 against
S. aureusMW2 is ~2 μg/mL (Table 1). As shown in Fig 4B, 10 μg/mL NH125 not only induced
rapid membrane permeabilization, but also resulted in a dramatic decrease in the viability of
MRSA persisters. To confirm the correlation between membrane permeabilization and viabili-
ty, we tested 5 sample compounds also identified in the C. elegans—MRSA screen that did not
have activity in the SYTOX Green assay and found that they did not decrease CFU counts
Fig 3. Validation of SYTOXGreen assay robustness. To test the robustness of the SYTOXGreen assay, the Z’-factor was calculated from fluorescence
intensity data from a 384-well plate where half of the wells contained 0.1% DMSO (negative control, open circles) and the remaining wells contained 10X MIC
lysostaphin (A) or 10X MIC nisin (B) (positive controls, solid circles). Fluorescence was measured with an excitation wavelength of 485 nm and an emission
wavelength of 525 nm after incubation in the dark for 1 h. The Z’-factors for each assay were 0.767 (A) and 0.712 (B).
doi:10.1371/journal.pone.0127640.g003
Fig 4. NH125 kills MRSA persisters by inducingmembrane permeabilization. (A) The chemical structure of NH125. (B) MRSA persisters were treated
with 10 μg/mL NH125. Membrane permeabilization (open circles) was measured spectrophotometrically by monitoring the uptake of SYTOXGreen
(excitation wavelength of 485 nm and an emission wavelength of 525 nm). Colony forming unit counts of persisters (solid circles) was measured by serial
dilution and plating on TSA plates. (C) MRSA persisters were treated with several concentrations of NH125: 10X MIC (20 μg/mL, circles), 5X MIC (10 μg/mL,
squares), 2.5X MIC (5 μg/mL, triangles), and 1X MIC (2 μg/mL, inverted triangles). Colony forming unit counts of persisters was measured by serial dilution
and plating on TSA plates. The data points on the x-axis are below the level of detection (2x102 CFU/mL). Results are shown as means ± s.d.; n = 3.
doi:10.1371/journal.pone.0127640.g004
Screening of Small Molecules against Persisters
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(data not shown). Next, we assessed the killing efficiency of NH125 on MRSA persisters at vari-
ous NH125 concentrations. 2.5X MIC (5 μg/mL) NH125 was sufficient to completely eradicate
MRSA persisters within 1 h, and 1X MIC (2 μg/mL) killed 99.999% of MRSA persisters within
4 h (Fig 4C).
One of the advantages of the SYTOX Green screening method is that positive hits that kill
persister cells by permeabilizing the membrane should also be able to kill non-persister cells.
Like lysostaphin [20] and nisin [22], the correlation between viability and membrane perme-
ability was also observed in growing MRSA treated with 10 μg/ml NH125 (S4 Fig).
NH125 kills and disrupts MRSA biofilms
Since persisters in biofilms are known to be responsible for antibiotic tolerance of biofilms
[44,45], we reasoned that NH125 would be effective in eradicating biofilms. First, we assessed
the ability of NH125 to kill MRSA cells in biofilms. For these experiments, MRSA biofilms stat-
ically cultured on 13 mmmixed cellulose membranes for 24 h at 37°C were treated with vanco-
mycin or NH125 at 10X MIC for 24 h. Individual cells were freed from the biofilm matrix by
sonication and cell viability was measured with CFU counts. As with planktonic persisters,
vancomycin was unable to kill MRSA cells in biofilms (Fig 5A). In contrast, NH125 killed over
99% of MRSA biofilm cells at 20 μg/mL (Fig 5A).
In addition to killing cells within biofilms, we assessed the ability of NH125 to disassemble
biofilm biomass. MRSA biofilms formed in a 96-well microtiter plate for 48 h at 37°C were
treated with various concentrations of vancomycin or NH125 (5X MIC to 160X MIC) for 24 h.
The entire biofilm biomass was quantified using crystal violet, a cationic dye that stains all
components of biofilms including cells and EPS [46,47]. Up to 160X MIC of vancomycin was
unable to disrupt MRSA biofilms (Fig 5B). However, 10X MIC of NH125 removed 50% of bio-
film biomass, and 80X MIC of NH125 completely disassembled the biofilm (Fig 5B). These re-
sults indicate that NH125 is able to effectively penetrate the EPS matrix, a protective “shield”
around biofilms, and kill persister cells as well as disrupting established biofilms.
Discussion
S. aureus is one of the most dangerous Gram-positive pathogens in the context of human
health. Up to 30% of individuals are carriers of S. aureus, which can cause a range of infectious
diseases from acute to chronic infections in both healthy individuals and immunocompro-
mised patients such as those with cancer and AIDS [4,48–54]. MRSA exhibiting resistance to
commonly prescribed beta-lactam antibiotics is increasingly prevalent in hospitals as well as
the community at large and has become an important public health problem [55]. Since MRSA
can form persisters and is associated with chronic infection [56], development of drugs against
MRSA persisters would be a significant advance in the treatment of MRSA infections.
Table 1. Minimal inhibitory concentration (MIC) against S. aureusMW2.
Compound MIC (μg/mL)
Gentamicin 2
Vancomycin 1
Ciproﬂoxacin 0.5
Lysostaphin 0.125
Nisin 8
NH125 2
doi:10.1371/journal.pone.0127640.t001
Screening of Small Molecules against Persisters
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To date, a variety of strategies have been used to kill persisters formed by S. aureus and
MRSA. The first strategy was to facilitate the uptake of aminoglycosides into MRSA persisters.
Although most biosynthetic processes that are targets for antibiotics are minimized in persist-
ers, proteins are synthesized at a low level, and therefore, aminoglycosides can be effective
against persisters [26,57]. However, the uptake of aminoglycosides is minimal in persisters due
to the inactive state of transport mechanisms [26,57,58]. Allison et al. reported that metabolites
such as glucose, mannitol, or fructose can make S. aureus persisters aminoglycoside-susceptible
by increasing the proton motive force of persister cell membranes [26]. Schmidt et al. engi-
neered tobramycin by attachment of 12 amino acids, which promotes the uptake of tobramycin
and subsequent killing of S. aureus persisters [57]. A second strategy was to induce protein deg-
radation in persister cells by activating a protease. Conlon et al. identified ADEP4 that kills
MRSA persisters by activating the ClpP protease, which subsequently leads to non-specific deg-
radation of over 400 proteins including several that are essential for bacterial survival [34]. The
third strategy was to directly attack structural components of the cell envelope such as the
membrane or cell wall. As reviewed in Hurdle et al., many membrane active agents such as
HT61 are known to kill S. aureus persisters [17]. In addition, Gutiérrez et al. reported that the
phage endolysin LysH5 is able to eradicate S. aureus persisters by hydrolyzing peptidoglycan
[59]. However, a screening method for systematically identifying drugs targeting MRSA per-
sisters has not previously been developed.
Based on the fact that cell envelope-targeting agents can directly and indirectly cause mem-
brane permeabilization, which is correlated with bactericidal activity [20,22,23], we devised a
HTS using SYTOX Green to discover new antimicrobial agents that are effective against MRSA
persisters. Statistical evaluation of assay robustness showed that the assay is suitable for a large-
scale screen. The SYTOX Green assay should also be broadly applicable for screens for drugs
Fig 5. NH125 eradicates MRSA biofilms. (A) MRSA biofilms formed on 13 mm cellulose ester membranes for 24 hours were treated with 10X MIC of
vancomycin (Van) or NH125 for 24 h. Survival was measured by comparing the number of viable cells in biofilms between non-treated and treated samples.
(B) MRSA biofilms grown in a 96-well microtiter plate for 48 h were treated with the indicated concentration of vancomycin or NH125 for 24 h. The remaining
biofilms were stained with 0.1% crystal violet dissolved with 95% ethanol and OD590 nm was measured. Results are shown as means ± s.d.; n = 3.
doi:10.1371/journal.pone.0127640.g005
Screening of Small Molecules against Persisters
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effective against persisters of other multidrug-resistant pathogens since SYTOX Green shows
selective permeability in both Gram-positive and Gram-negative bacteria [24]. For example,
we found a correlation between membrane permeability and viability of E. coli persisters after
treatment with polymyxin B [60], a membrane active antibiotic effective against Gram-negative
bacteria (S6B Fig). By conducting a pilot screen with 101 anti-MRSA agents from a previously
conducted C. elegans-MRSA screen for compounds that block the ability of MRSA to kill the
nematodes, we identified NH125, which has low toxicity but strong antimicrobial property
against MRSA persisters.
In our “proof of principle” screen of candidate antibiotics, we identified NH125 as a com-
pound that is able to kill MRSA persisters. NH125 is already known to have antimicrobial
properties with antibiotic activity (MIC 0.39–3.12 μg/mL) against drug-resistant Gram-positive
bacteria, such as oxacillin-resistant S. aureus, penicillin G-resistant Streptococcus pneumoniae,
and vancomycin-resistant Enterococcus faecalis [41]. A recent study revealed that NH125 in-
hibits histidine kinases of bacterial two component signal transduction systems (TCS) by in-
ducing non-specific aggregation of the histidine kinases [61]. NH125 has also been investigated
as a potential antineoplastic drug with activity against eukaryotic elongation factor 2 kinase
(eEF2K), which was shown to be due to nonspecific colloidal aggregation [62]. Based on the
known kinase aggregation activity of NH125 [61,62], a possible mechanism by which NH125
kills persister cells may be by binding and aggregating kinases on the MRSA cell membrane,
causing structural changes that result in membrane permeabilization and death.
Although many membrane-damaging agents have excellent anti-MRSA properties, includ-
ing a low MIC, rapid killing rate, and low probability for developing resistance, they have a ten-
dency to cause toxicity in mammals [63,64]. However, our starting library of 101 anti-MRSA
agents identified using the C. elegans-MRSA HTS was expected to be enriched for nontoxic
compounds, since the endpoint of the assay is enhanced survival of the nematodes in the pres-
ence of MRSA. In fact, the invertebrate nematode C. elegans has been used as a model for as-
sessing toxicity of many chemicals, including heavy metals, environmental pollutants, organic
solvents, and neurotoxins [65–67]. Moreover, many studies have shown a strong correlation in
toxicity between C. elegans and rodents [68,69]. In the C. elegans-MRSA HTS, 7.5 μg/mL
NH125 kills MRSA but shows no toxicity to C. elegans (S7 Fig). Consistent with this result, up
to 30 μM (15.8 μg/mL) NH125 has been reported to be nontoxic to sea urchin eggs [70]. Be-
cause of low toxicity, the kinase inhibitory activity of NH125 has been intensively studied in
human cells and mice [43,71–74]. Considering 2 μg/mL of NH125 (equivalent to 1X MIC) kills
99.999% of MRSA persister cells within 4 h, we believe NH125 is a good candidate drug that
warrants further studies as a therapeutic against MRSA persisters.
In summary, we have devised a fluorescence-based HTS for identifying drugs that eradicate
MRSA. Using this screening method, we identified NH125, a compound that effectively kills
MRSA persisters by inducing rapid membrane permeabilization but has selectivity to bacteria.
Furthermore, NH125 kills MRSA persisters in biofilms and eradicates established MRSA bio-
films. The screening method we developed can be used as a large-scale screening platform for
antibiotic drug discovery against persisters of a broad range of pathogens. NH125, and/or de-
rivatives of this molecule, warrant further evaluation as antibiotics for treatment of persistent
or chronic infections.
Supporting Information
S1 Fig. Isolated MRSA persisters are tolerant to 100X MIC conventional antibiotics. A
MRSA overnight culture was treated with 10X MIC (20 μg/mL) gentamicin for 4 h and the
titer of viable cells was determined. After the 4 h treatment with gentamicin, the culture was
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treated with additional antibiotics at the indicated concentrations (100X MIC) for an addition-
al 4 h, followed by once again determining the titer of viable cells. Results are shown as
means ± s.d.; n = 3. Gm: gentamicin, Cipro: ciprofloxacin, Van: vancomycin.
(TIFF)
S2 Fig. Lysostaphin and nisin kill MRSA persisters by inducing membrane permeabiliza-
tion in a dose-dependent manner.MRSA persisters were treated with 5X MIC lysostaphin
(A), 2.5X MIC lysostaphin (B),1X MIC lysostaphin (C), 5X MIC nisin (D), 2.5X MIC nisin (E),
or 1X MIC nisin (F). Membrane permeabilization (open circles) was measured spectrophoto-
metrically by monitoring the uptake of SYTOX Green (excitation wavelength of 485 nm and
an emission wavelength of 525 nm). Colony forming unit counts of persisters (solid circles)
were measured by serial dilution and plating on TSA plates. The data points on the x-axis are
below the level of detection (2x102 CFU/mL). Results are shown as means ± s.d.; n = 3.
(TIFF)
S3 Fig. Conventional antibiotics do not kill MRSA persisters or induce membrane permea-
bilization.MRSA persisters were treated with 10X MIC (20 μg/mL) gentamicin, 10X MIC
(10 μg/mL) vancomycin (B), or 10X MIC (5 μg/mL) ciprofloxacin (C). Membrane permeabili-
zation (open circles) was measured spectrophotometrically by monitoring the uptake of
SYTOX Green (excitation wavelength of 485 nm and an emission wavelength of 525 nm). Col-
ony forming unit counts of persisters (solid circles) was measured by serial dilution and plating
TSA plates. Results are shown as means ± s.d.; n = 3.
(TIFF)
S4 Fig. NH125 kills growing MRSA by inducing membrane permeabilization. Growing
MRSA was treated with 10 μg/ml NH125. Membrane permeabilization (open circles) was mea-
sured spectrophotometrically by monitoring the uptake of SYTOX Green (excitation wave-
length of 485 nm and an emission wavelength of 525 nm). Colony forming unit counts of
persisters (solid circles) were measured by serial dilution and plating on TSA plates. The data
points on the x-axis are below the level of detection (2x102 CFU/mL). Results are shown as
means ± s.d.; n = 3.
(TIFF)
S5 Fig. Increase of ciprofloxacin concentration up to 1000XMIC does not affect the viabili-
ty of E. coli persisters. An E. coliMG1655 overnight culture was treated with 10X MIC
(0.3 μg/mL), 100X MIC (3 μg/ml), or 1000X MIC (30 μg/ml) ciprofloxacin for 4 h and the titer
of viable cells was determined. Results are shown as means ± s.d.; n = 3. Gm: gentamicin,
Cipro: ciprofloxacin, Van: vancomycin.
(TIFF)
S6 Fig. Polymyxin B kills E. coli persisters by inducing membrane permeabilization. E. coli
MG1655 persisters were treated with 0.1% DMSO (A), 10X MIC (20 μg/ml) polymyxin B (B),
10X MIC (0.3 μg/mL) ciprofloxacin (C), 10X MIC (160 μg/mL) ampicillin (D), or 10X MIC
(40 μg/mL) gentamicin (E). Membrane permeabilization (open circles) was measured spectro-
photometrically by monitoring the uptake of SYTOX Green (excitation wavelength of 485 nm
and an emission wavelength of 525 nm). Colony forming unit counts of persisters (solid cir-
cles) were measured by serial dilution and plating on TSA plates. The data points on the x-axis
are below the level of detection (2x102 CFU/mL). Results are shown as means ± s.d.; n = 3.
(TIFF)
S7 Fig. NH125 has antimicrobial activity against MRSA but no toxicity to C. elegans. 15
adult worms were transferred in 384-well plates. Each well contained 70 μL media including
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70%M9 buffer, 19% sheath solution (Union Biometrica Part no. 300-5101-000), 10% TSB, and
1% DMSO. The bacterial concentration in each well was adjusted to OD600 0.04, and the final
concentration of drugs was 7.5 μg/mL. After incubation in a humidified chamber at 25°C for 5
days, the worms were washed 8-times with M9 buffer and stained with 0.7 μM SYTOX Orange
for staining dead worms. The plates were imaged using an Image Xpress Micro automated mi-
croscope (Molecular Devices), capturing both transmitted light and TRITC (535 nm excitation,
610 nm emission) fluorescent images with a 2X objective.
(TIFF)
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